153 related articles for article (PubMed ID: 28350001)
1. A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gong G; Kwon MJ; Han J; Lee HJ; Lee SK; Lee JE; Lee SH; Park S; Choi JS; Cho SY; Ahn SH; Lee JW; Cho SR; Moon Y; Nam BH; Nam SJ; Choi YL; Shin YK
Sci Rep; 2017 Mar; 7():45554. PubMed ID: 28350001
[TBL] [Abstract][Full Text] [Related]
2. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
3. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M; Rudas M; Jakesz R; Dubsky P; Fitzal F; Singer CF; Dietze O; Greil R; Jelen A; Sevelda P; Freibauer C; Müller V; Jänicke F; Schmidt M; Kölbl H; Rody A; Kaufmann M; Schroth W; Brauch H; Schwab M; Fritz P; Weber KE; Feder IS; Hennig G; Kronenwett R; Gehrmann M; Gnant M;
Clin Cancer Res; 2011 Sep; 17(18):6012-20. PubMed ID: 21807638
[TBL] [Abstract][Full Text] [Related]
4. Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
Fujiki Y; Kashiwaba M; Sato M; Kawano J; Teraoka M; Kanemitsu S; Rai Y; Taira T; Sagara Y; Ohi Y; Jo U; Lee YW; Lee SB; Gong G; Shin YK; Kwon MJ; Sagara Y
Breast Cancer; 2024 Jan; 31(1):31-41. PubMed ID: 37812303
[TBL] [Abstract][Full Text] [Related]
5. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
8. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
9. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
12. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.
Kronenwett R; Bohmann K; Prinzler J; Sinn BV; Haufe F; Roth C; Averdick M; Ropers T; Windbergs C; Brase JC; Weber KE; Fisch K; Müller BM; Schmidt M; Filipits M; Dubsky P; Petry C; Dietel M; Denkert C
BMC Cancer; 2012 Oct; 12():456. PubMed ID: 23039280
[TBL] [Abstract][Full Text] [Related]
13. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
14. Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Kwon MJ; Lee JE; Jeong J; Woo SU; Han J; Kang BI; Kim JE; Moon Y; Lee SB; Lee S; Choi YL; Kwon Y; Song K; Gong G; Shin YK
Front Oncol; 2019; 9():667. PubMed ID: 31404265
[No Abstract] [Full Text] [Related]
15. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
[TBL] [Abstract][Full Text] [Related]
17. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
18. Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2- Early Breast Cancer.
Kwon MJ; Ryu JM; Cho SY; Nam SJ; Kim SW; Lee J; Lee SJ; Park JY; Park HY; Hong S; Kim K; Han J; Moon Y; Shin YK; Lee JE
Front Oncol; 2021; 11():588728. PubMed ID: 33708625
[TBL] [Abstract][Full Text] [Related]
19. [Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer].
Zhang YN; Zhou YD; Mao F; Guan JH; Lin Y; Wang XJ; Shen SJ; Wang CJ; Yao R; Sun Q
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):110-114. PubMed ID: 29502370
[No Abstract] [Full Text] [Related]
20. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
